Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy + NALIRI (irinotecan liposome + 5-FU/LV) + Adebrelimab for unresectable biliary tract tumors (first-line)
ChiCTR2500107609Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Aug 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab, irinotecan liposome, fluorouracil and folinic acid in biliary cancer, intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (eCCA) and 1 more, sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Progression-free survival (PFS). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
adebrelimabirinotecan liposomefluorouracilfolinic acid
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)extrahepatic cholangiocarcinoma (eCCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2500107609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107609.